Relmada Therapeutics, Inc.
RLMDHealthcareNASDAQBiotechnology
Scan Results
Daily timeframeRelmada Therapeutics, Inc. operates as a clinical-stage biotechnology company in the United States. With a market capitalization of $697.5M, it sits in small-cap territory. The company focuses on the development of NDV-01, a controlled-release intravesical formulation of gemcitabine and docetaxel, which is in Phase 2 clinical trial for patients with aggressive forms of non-muscle invasive bladder cancer; and Sepranolone, a neurosteroid epimer of allopregnanolone, which is Phase 2b-ready for the potential treatment of prader-willi syndrome, tourette syndrome, excessive tremor, and other diseases related to excessive GABAergic activity.
Market Cap
$697.5M
Beta
—
P/E (TTM)
—
P/E (Fwd)
-16.22
EPS (TTM)
$-1.09
EPS (Fwd)
$-0.41
ROE
-25.6%
ROA
-14.4%
Cash
$116.4M
Total Debt
$110,247
Free CF
-$7.7M
52W Change
839.3%
Annual Financials
Cash vs Debt
Relmada Therapeutics, Inc. holds $116.4M in cash against $110K in total debt, giving it a net cash position. This means the company could theoretically pay off all its debt and still have cash remaining. Free cash flow is running at -$7.7M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. Return on equity stands at -25.6%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits.
The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for Relmada Therapeutics, Inc. and its sector.